TaiGen Successfully Completes TG-1000 Phase III Study
2024-04-18
临床3期上市批准
TAIPEI, April 17, 2024 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of all influenza symptoms after TG-1000 treatment was shorter than that of the placebo group, with a statistically significant difference. TG-1000 also possesses great safety profile, and there was no clinically significant safety concerns observed. Furthermore, TaiGen will advance cooperation and development negotiation in Europe, the U.S., and other Asian countries. It is expected that in the second half of the year, Joincare Pharmaceutical will file a new drug application for TG-1000 in mainland China.
The primary endpoint of the study, the median time to alleviation of all influence symptoms of TG-1000 group (60.9 hours), was shorter than that of the placebo group (87.9 hours). It shows that TG-1000 effectively shortens the time for influenza symptom alleviation, which is statistically significant (PChina influenza surveillance data, the majority of patients admitted to the Phase III trial are influenza virus A infected.
Kuo-Lung Huang, Chairman and CEO of TaiGen commented on the trial results, stating that "The surge in influenza cases from 2023 to 2024 indicates the trend of coexistence between influenza viruses and humans. The positive outcome of TG-1000 Phase III trial represents another opportunity for an innovative drug to enter clinical use. TaiGen holds a cautiously optimistic attitude." He mentioned that the sales of influenza medication in mainland China exceeded RMB 6 billion in 2023, returning to the market size before the COVID-19 epidemic. The potential market size for innovative flu medication in the future can be expected.
About TaiGen Biotechnology
TaiGen Biotechnology, with a subsidiary in Beijing, China, was founded in 2001 and became listed on the Taiwan OTC Stock Market in 2014. TaiGen is a fully-integrated pharmaceutical company dedicated to the development of innovative small molecule drugs with a focus on anti-infective drug research. Its flagship product, non-fluorinated quinolone antibiotic Taigexyn® (Nemonoxacin), has obtained marketing approvals in Taiwan, mainland China, and Russia. The influenza antiviral TG-1000 has completed the phase III clinical trial.
SOURCE TaiGen
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。